Article Information
History
- September 28, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Pritha Chatterjee1,
- Vinicius Canale1,
- Stephanie J. King1,
- Ali Shawki1,
- Hillmin Lei1,
- Michael Haddad2,
- Casey M. Gries1,
- Dermot P.B. McGovern3,
- James Borneman4 and
- Declan F. McCole1,*
- 1Division of Biomedical Sciences, University of California, Riverside, Riverside, California
- 2Department of Biology, University of California, Riverside, Riverside, California
- 3Department of Gastroenterology, Cedars-Sinai Medical Center, Los Angeles, California
- 4Department of Microbiology and Plant Pathology, University of California, Riverside, California
- ↵*Corresponding Author:
Declan F. McCole, PhD, Division of Biomedical Sciences, School of Medicine, University of California, Riverside, 307 School of Medicine Research Building, 900 University Avenue, Riverside, CA92521; Tel: (951) 827-7785; E-mail: declan.mccole{at}ucr.edu
Posted September 28, 2024.
The JAK inhibitor, Tofacitinib, Corrects the Overexpression of CEACAM6 and Limits Susceptibility to AIEC Caused by Reduced Activity of the IBD Associated Gene, PTPN2
